The Health Technology Assessment (HTA) Council releases its preliminary recommendation on the government financing of apixaban, dabigatran, and rivaroxaban for the prevention of myocardial infarction, cerebrovascular diseases and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroups of NVAF patients through its inclusion in the Philippine National Formulary.Appeals will be accepted from continue reading : [Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of DOACs for Nonvalvular Atrial Fibrillation
[Announcement] HTA Council Releases Its Preliminary Recommendation on the Non-Financing of Cerebrolysin for Post Ischemic Stroke
The Health Technology Assessment (HTA) Council releases its preliminary recommendation on the non-government financing of cerebrolysin in combination with rehabilitation or standard of care for the treatment of adults post-ischemic stroke through its non-inclusion in the Philippine National Formulary.Appeals will be accepted from 17 March 2023 to 31 March 2023 Kindly see full advisory:CALL FOR continue reading : [Announcement] HTA Council Releases Its Preliminary Recommendation on the Non-Financing of Cerebrolysin for Post Ischemic Stroke
HTAC Guidance: PNF Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe
(Updated as of 14 March 2023) On 24 January 2023, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of recombinant Human Erythropoietin (epoetin alfa) 4000 IU/mL solution for injection (IV/SC), 1mL pre-filled syringe, for the management of chemotherapy-induced anemia in patients with non-myeloid disease through its minor inclusion continue reading : HTAC Guidance: PNF Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe
HTAC Guidance: PNF Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe
(Updated as of 14 March 2023) On 24 January 2023, the OIC-Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation for the government financing of Filgrastim 300 mcg/0.9 mL solution (IV, SC), 0.9 mL pre-filled syringe, for the treatment of neutropenia in patients undergoing bone marrow transplantation and patients receiving myelosuppressive cancer chemotherapy through continue reading : HTAC Guidance: PNF Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe
[Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of Dapagliflozin for Patients with Type 2 Diabetes Mellitus
As of 07 March 2023, the Health Technology Assessment Council (HTA Council) has completed the assessment and deliberation for the preliminary recommendation on dapagliflozin 10 mg single-dose film-coated tablets as add-on treatment for adults with Type 2 Diabetes Mellitus including those who have or are at high risk of cardiovascular disease and/or diabetic neuropathy. The continue reading : [Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of Dapagliflozin for Patients with Type 2 Diabetes Mellitus